JanOne stock trades quietly on Nasdaq as investors focus on early-stage pain therapy pipeline

Published on 09/20/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JanOne stock is moving in a tight range on Nasdaq as of September 18, 2026, reflecting its low tens of millions USD market capitalization and speculative healthcare profile. The company’s most recent fiscal results show single-digit million revenue, underlining its early-stage status.

JAN, US47035L1026, Illustration mit AI erstellt.

JanOne stock (ISIN US47035L1026) is trading at a low single-digit dollar level on Nasdaq, with the latest completed session as of September 18, 2026 highlighting modest absolute price moves against a small free float and a market capitalization in the low tens of millions USD range.

Small-cap healthcare name with limited liquidity

JanOne Inc., a healthcare and biotechnology company focused on pain management and neurology, continues to trade on Nasdaq under the ticker JAN, where its shares change hands at a low single-digit dollar price as of September 18, 2026.

According to a recent overview of JanOne stock published on September 19, 2026, the company’s market capitalization stands in the low tens of millions USD, reflecting its position as a speculative small-cap rather than a mature large-scale operator in the sector.Ad-hoc-news.de

Recent fundamentals underscore early commercialization stage

On the fundamentals side, the most recent available reported figures within the freshness window come from JanOne’s latest fiscal results for the most recent fiscal year within the last 24 months and a subsequent interim period, as summarized on the company’s investor relations pages and reputable financial portals as of mid-2026.JanOne

According to reporting for JanOne’s most recent fiscal year within this 24-month window, annual revenue stood in the single-digit million USD range, making it clear that the company is still in an early commercialization phase rather than generating tens or hundreds of millions in sales.Ad-hoc-news.de

In practical terms, that means that even incremental changes in revenue or operating expenses can have a noticeable percentage impact on JanOne’s margins and net results, which investors in speculative healthcare names typically monitor closely over each new reporting period.

Price range and recent trading behavior

The latest same-week trading commentary indicates that in the most recent completed Nasdaq session before September 19, 2026, JanOne stock closed at a low single-digit dollar price, with intraday moves that remained contained inside its broader 52-week trading band.Ad-hoc-news.de

The same overview notes that daily percentage changes in JanOne stock can be significant relative to the small float, even if the absolute move in dollar terms appears modest against the low single-digit price level.Ad-hoc-news.de

For investors, this combination of a low tens of millions USD market capitalization as of September 18, 2026 and single-digit million annual revenue in the most recent fiscal year underscores that JanOne stock offers exposure to early-stage pain therapy development with a correspondingly high sensitivity to clinical and regulatory milestones.

Stock level and investor takeaway

As of September 18, 2026, JanOne stock closed on Nasdaq at a low single-digit dollar price in USD, with the company’s market capitalization in the low tens of millions USD and trading volumes reflecting its status outside the major equity indices.